Radiopharm Theranostics Ltd (RADX) EBIT (2023 - 2026)

Radiopharm Theranostics (RADX) has reported EBIT for 4 consecutive years, with -$711294.1 the latest figure, recorded in Q2 2026.

• On a quarterly basis, EBIT rose 98.14% year-over-year to -$711294.1 in Q2 2026; TTM through Jun 2026 was -$73.6 million, a N/A change from a year earlier, with the FY2026 full-year figure at -$385651.8, up 98.99% from the prior year.
• EBIT was -$711294.1 for Q2 2026 at Radiopharm Theranostics, up from -$38.2 million in the prior quarter.
• Over five years, EBIT peaked at -$263338.9 in Q2 2024 and troughed at -$38.2 million in Q2 2025.
• A 4-year average of -$18.4 million and a median of -$17.6 million in 2023 frame the typical range for EBIT.
• Across the five-year window, EBIT jumped 99.24% in 2024 and slumped 14396.1% in 2025, its largest moves.
• Over 4 years, EBIT stood at -$34.5 million in 2023, then jumped by 99.24% to -$263338.9 in 2024, then tumbled by 14396.1% to -$38.2 million in 2025, then jumped by 98.14% to -$711294.1 in 2026.
• The last three EBIT figures came in at -$711294.1 (Q2 2026), -$38.2 million (Q2 2025), and -$263338.9 (Q2 2024), per Business Quant data.